Is Divis Laboratories Ltd (DIVISLAB) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Divis Laboratories Ltd is a good quality company .

Is Divis Laboratories Ltd (DIVISLAB) undervalued or overvalued?

The key valuation ratios of Divis Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Divis Laboratories Ltd (DIVISLAB) share price return in the past 10 years?

Divis Laboratories Ltd share price has appreciated 19.6% annually (CAGR) over the past ten years.

Is Divis Laboratories Ltd (DIVISLAB) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Divis Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Divis Laboratories Ltd (DIVISLAB)?

Company share prices are keep on changing according to the market conditions. The current trading price of Divis Laboratories Ltd (DIVISLAB) on 17-Apr-2026 16:59:59 at 16:59 is 6228.95.

What is the P/E ratio of Divis Laboratories?

The latest standalone P/E ratio of Divis Laboratories as of 17-Apr-2026 is 65.67.

What is the P/B ratio of Divis Laboratories Ltd (DIVISLAB)?

The latest standalone P/B ratio of Divis Laboratories Ltd (DIVISLAB) as of 17-Apr-2026 is 10.37.

What is the 52-week high and low of Divis Laboratories Ltd (DIVISLAB)?

The 52-week high of Divis Laboratories Ltd (DIVISLAB) is Rs. 7077.70 and the 52-week low is Rs. 5637.50.

Divis Laboratories Ltd (DIVISLAB) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Divis Laboratories Ltd (DIVISLAB)
Brand: Divis Laboratories

Key Metrics

Market Cap

₹1,65,359 Cr.

P/E Ratio

66.70

Price to Book (P/B)

10.34

Price to Sales (P/S)

16.03

EV/EBITDA

42.34

Return on Capital Employed (ROCE)

20.45%

Current Price

₹6,229

Return on Equity (ROE)

15.35%

Return on Assets (ROA)

13.02%

Operating Profit Margin

31.8%

Net Profit Margin

23.41%

Gross Profit Margin

35.3%

Book Value per Share

₹602.6

Sales Growth (YoY)

19.31%

Sales Growth (3 Years)

1.47%

Operating Profit Growth (1 Year)

34.59%

Operating Profit Growth (3 Years)

-8.54%

Net Profit Growth (1 Year)

36.94%

52-Week Low / High

₹5,638 / 7,078

Net Profit Growth (3 Years)

-80.51%

Dividend Yield

0.52%

Promoter Holding

51.88%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Divis Laboratories Ltd?

Divis Laboratories Ltd revenue growth is 19.3% for FY-2025 , which is above its 5 year CAGR of 11.7% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Divis Laboratories Ltd?

Promoters hold 51.88% of the Divis Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Divis Laboratories Ltd vs industry peers?

Divis Laboratories Ltd revenue CAGR is 11.65% , compared to the industry median CAGR of 10.76% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Divis Laboratories Ltd belong to?

Divis Laboratories Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Divis Laboratories Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 19.8% based on the current price.

DeciZen - make an informed investing decision on Divis Lab

Based on:

Data
Research

Consolidated basis

1. Right Stock

2. Right Price

Price Chart

3. Right Time ⓘ

#Likely Future 5 Year CAGR.

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation

3. Price Trend

Divis Laboratories stock performance

Key Ratios

Is Divis Laboratories Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	35.6%	28.8%	21.7%	28.5%	25.4%	32.1%	35.1%	19.4%	16.5%	20.5%	-
Value Creation Index ⓘ	2.2	1.6	0.9	1.5	1.3	1.9	2.1	0.7	0.5	0.8	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	3,776	4,064	3,891	4,946	5,394	6,969	8,960	7,767	7,845	9,360	10,314
Sales YoY Gr.	-	7.6%	-4.3%	27.1%	9.1%	29.2%	28.6%	-13.3%	1%	19.3%	-
Adj EPS ⓘ	41.5	41	32.5	50.2	49.4	75	110.5	65.3	59.6	81.4	93.4
YoY Gr.	-	-1.4%	-20.7%	54.5%	-1.5%	51.8%	47.4%	-40.9%	-8.8%	36.6%	-
BVPS (₹) ⓘ	161.7	201.8	223.2	262.1	275.4	350.2	441.8	481.8	512.1	564.9	602.6
Adj Net Profit ⓘ	1,102	1,087	862	1,331	1,311	1,990	2,933	1,734	1,582	2,160	2,479
Cash Flow from Ops. ⓘ	1,038	1,150	776	954	1,216	1,947	1,912	2,459	1,261	1,653	-
Debt/CF from Ops. ⓘ	0	0	0.1	0.1	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	10.6%	11.7%	1.5%	19.3%
Adj EPS ⓘ	7.8%	10.5%	-9.7%	36.6%
BVPSⓘ	14.9%	15.5%	8.5%	10.3%
Share Price	19.6%	10.3%	24%	10.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	28.3	22.5	15.3	20.7	18.4	24	27.9	14.2	12	15.1	16
Op. Profit Mgn % ⓘ	37.7	36.6	32.6	37.9	33.9	41.2	43.3	30.5	28.2	31.8	32.9
Net Profit Mgn % ⓘ	29.2	26.7	22.2	26.9	24.3	28.6	32.7	22.3	20.2	23.1	24
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	-
Working Cap Days ⓘ	245	268	371	307	294	247	239	293	277	268	169
Cash Conv. Cycle ⓘ	156	144	154	142	153	126	130	182	183	170	142

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	94.9	93.4
TTM Sales (₹ Cr.)	10,131	10,314
BVPS (₹) ⓘ	600.8	602.6
Reserves (₹ Cr.) ⓘ	15,896	15,943
P/BV ⓘ	10.37	10.34
PE ⓘ	65.67	66.70

From the Market
52 Week Low / High (₹)	5637.50 / 7077.70
All Time Low / High (₹)	7.70 / 7077.70
Market Cap (₹ Cr.)	1,65,359
Equity (₹ Cr.)	53.1
Face Value (₹)	2
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Divis Lab - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	3,776	4,064	3,891	4,946	5,394	6,969	8,960	7,767	7,845	9,360
Operating Expenses ⓘ +	2,358	2,617	2,629	3,073	3,571	4,108	5,079	5,398	5,639	6,391
Manufacturing Costs	350	368	411	462	540	617	758	897	902	881
Material Costs	1,505	1,534	1,534	1,825	2,109	2,324	2,967	3,053	3,129	3,725
Employee Cost	361	500	456	542	621	826	946	975	1,094	1,243
Other Costs ⓘ	142	215	227	244	302	342	407	473	514	542
Operating Profit ⓘ	1,418	1,447	1,263	1,873	1,823	2,861	3,881	2,369	2,206	2,969
Operating Profit Margin (%)	37.6%	35.6%	32.4%	37.9%	33.8%	41.1%	43.3%	30.5%	28.1%	31.7%
Other Income ⓘ +	97	75	113	156	190	63	116	345	339	352
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	5	3	2	5	7	2	2	2	4	3
Depreciation ⓘ	118	123	142	169	186	256	312	343	378	402
Profit Before Tax ⓘ	1,393	1,395	1,231	1,855	1,819	2,666	3,684	2,369	2,163	2,916
Tax ⓘ	267	335	354	502	443	682	723	545	563	725
Profit After Tax	1,126	1,060	877	1,353	1,377	1,984	2,960	1,824	1,600	2,191
PAT Margin (%)	29.8%	26.1%	22.5%	27.4%	25.5%	28.5%	33.0%	23.5%	20.4%	23.4%
Adjusted EPS (₹)	42.4	40.0	33.0	51.0	51.9	74.8	111.5	68.8	60.4	82.7
Dividend Payout Ratio (%)	24%	25%	30%	31%	31%	27%	27%	44%	50%	36%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	4,293	5,357	5,925	6,957	7,310	9,295	11,728	12,767	13,571	14,969
Share Capital ⓘ	53	53	53	53	53	53	53	53	53	53
Reserves ⓘ	4,240	5,304	5,872	6,904	7,257	9,242	11,675	12,714	13,518	14,916
Debt +	42	36	63	106	34	0	0	0	0	2
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	41	36	63	106	34	0	0	0	0	2
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	233	446	411	492	591	763	796	762	824	910
Others Liabilities ⓘ	330	1,590	1,948	1,240	1,491	1,329	2,095	1,334	1,542	1,836
Total Liabilities ⓘ	4,898	7,429	8,347	8,795	9,425	11,387	14,619	14,863	15,937	17,717
Fixed Assets
Net Fixed Assets ⓘ +	1,439	1,559	1,996	2,088	2,782	3,704	4,325	4,722	4,739	5,442
Gross Block	2,196	1,794	2,373	2,634	3,514	4,692	5,624	6,365	6,760	7,868
Accumulated Depreciation	757	235	377	546	732	988	1,299	1,643	2,021	2,426
CWIP ⓘ	264	444	120	492	920	711	470	212	778	1,022
Investments ⓘ	803	1,631	1,889	1,946	971	0	72	77	82	65
Inventories	1,208	1,320	1,351	1,772	1,864	2,145	2,829	3,000	3,184	3,236
Trade Receivables	881	901	1,014	1,163	1,413	1,677	2,424	1,793	2,156	2,731
Cash Equivalents	73	79	112	115	123	2,156	2,819	4,214	3,980	3,715
Others Assets ⓘ	230	1,496	1,864	1,219	1,352	995	1,681	845	1,018	1,506
Total Assets ⓘ	4,898	7,429	8,347	8,795	9,425	11,387	14,619	14,863	15,937	17,717

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	1,038	1,150	776	954	1,216	1,947	1,912	2,459	1,261	1,653
PBT ⓘ	1,393	1,395	1,231	1,855	1,819	2,666	3,684	2,369	2,163	2,916
Adjustment ⓘ	61	94	32	84	60	189	240	144	81	115
Changes in Working Capital ⓘ	-155	-37	-219	-500	-218	-264	-1370	419	-607	-554
Tax Paid ⓘ	-261	-302	-269	-484	-445	-644	-641	-473	-376	-824
Cash Flow From Investing Activity ⓘ +	-406	-1,140	-478	-685	-83	75	-2,195	-2,707	-269	-804
Capex	-396	-377	-274	-733	-1,183	-910	-713	-473	-1,003	-1,438
Net Investments	-67	-831	-285	-43	1,056	928	-1,549	-2,439	434	339
Others ⓘ	56	68	81	91	43	57	67	205	300	295
Cash Flow From Financing Activity ⓘ +	-631	2	-314	-246	-1,091	-35	-532	-797	-799	-799
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-2	-2	-1	-4	-6	-1	-0	0	-2	-2
Dividend Paid ⓘ	-531	0	-319	-265	-850	0	-531	-796	-796	-796
Others ⓘ	-98	5	6	23	-236	-34	-1	-1	-1	-1
Net Cash Flow ⓘ	0	13	-17	23	41	1,987	-816	-1,045	193	50

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	28.91	21.98	15.55	21	19.3	23.9	28.16	14.89	12.15	15.35
ROCE (%)	35.57	28.75	21.68	28.5	25.36	32.07	35.06	19.36	16.46	20.45
Asset Turnover Ratio	0.76	0.67	0.5	0.58	0.6	0.67	0.69	0.53	0.51	0.56
PAT to CFO Conversion(x)	0.92	1.08	0.88	0.71	0.88	0.98	0.65	1.35	0.79	0.75
Working Capital Days
Receivable Days	78	79	89	80	86	81	83	98	91	95
Inventory Days	114	112	125	114	122	105	101	136	143	125
Payable Days	56	81	102	90	94	106	96	93	93	85

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Divis Laboratories Ltd FAQs

The current trading price of Divis Lab on 17-Apr-2026 16:59 is ₹6,229.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Divis Lab stood at ₹1,65,359.1 Cr

The latest P/E ratio of Divis Lab as of 16-Apr-2026 is 65.67.

The latest P/B ratio of Divis Lab as of 16-Apr-2026 is 10.37.

The 52-week high of Divis Lab is ₹7,077.7 and the 52-week low is ₹5,637.5.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Divis Lab is ₹10,131 ( Cr.) .

About Divis Laboratories Ltd

Divi’s Laboratories Limited is a Company limited by shares, incorporated and domiciled in India. The Company is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. The Company is a public limited company and the Company’s equity shares are listed in BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) in India.

Business area of the company

The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.

Business Segments

Generic APIs
Custom Synthesis
Nutraceuticals

Products

Capecitabine
Carbidopa
Diltiazem HCl
Dextromethorphan Base
Dextromethorphan HBr
Fosphenytoin Sodium
Gabapentin
Iopamidol
Irbesartan
Levetiracetam
Levodopa
Mesalamine
Nabumetone
Naproxen
Naproxen Sodium
Niacin
Olmesartan Medoxomil
Phenylephrine HCl
Pregabalin
Proguanil HCl
Quetiapine Fumarate
Tamsulosin HCl
Telmisartan
Triprolidine HCl
Valacyclovir HCl
Valsartan
Venlafaxine HCl
Vigabatrin

Awards

2001:

Occupational Health and Safety Management System (OHSAS-18001)

2002:

May Day Award for Best Management

2003:

Shreshtha Suraksha Puraskar
Appreciation certificate for Meritorious performance in implementing the programmes of ‘Safe Guarding the Environment and Pollution Control’
Viswakarma Rashtriya Puraskar

2004:

Good Practice in Cleaner Production and Pollution Control

2005:

National Award for Excellence Water Management 2005
Appreciation certificate for Meritorious performance in implementing the programmes of ‘Safe Guarding the Environment and Pollution Control & Plantation work’.
May Day Award for Best Management

2006:

National Award for Excellence Water Management and Certificate for Water efficient unit.
National Award for Excellence Water Management and Certificate for Water efficient unit - Beyond the fence.
Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’.

2007:

Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’.

2008:

Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’ on the Occasion of the World Environment
Finalist Certificate

2009:

Certified and Awarded for ‘Best Green Belt Development’
Occupational Health and Safety Management System (OHSAS-18001:2007)
ISO 14001: 2004 (Re-Certification) ‘Environment Management System’

2011:

Best Green Belt Development.

2012:

India Business Leader Award ‘First Generation Entrepreneur of the Year’
Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
ISO 14001: 2004 (Re-Certification) ‘Environment Management System’.

2013:

ISO 14064 - 1: 2006 Green House Gas Accounting verification.
May Day award for Best Management

2014:

Winner of ‘Special Commendation’ for Golden Peacock Award for Corporate Social Responsibility

2015:

Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
May Day award for Best Management
ISO 14001: 2004 (Re-Certification) ‘Environment Management System’.

2018:

Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
ISO 14001 : 2018 (Re- certification) ‘Environmental Management System’.
May Day award for Best Management

Milestones

1990: Inception of Divi’s as Divi’s Research Centre(DRC)
1995: Setup First Manufacturing facility(Unit-1) near Hyderabad
2000: First USFDA Inspection
2002: Commenced New Manufacturing Facility (Unit 2) near Vishakhapatnam
2003: Divi’s Labs listed on Indian Stock Exchange
2007: Set up Nutraceuticals facility at Unit 2
2008: First MFDS(Korea) inspection
2010: Established New Research Centre at Hyderabad
2011: First EU GMP and Japan PMDA Inspection
2012: First TGA Inspection
2013: First Slovenian Medicines Agency inspection for Unit-II
2014: Divi’s reaches a milestone of 8700 employees
2014: First COFEPRIS inspection
2015: New corporate office inaugurated at Hyderabad
2015: New Pilot block with 160 Reactors and Kilo Lab
2016: First Anvisa (Brazil) inspection
2017: Divi’s reaches a milestone of 11,000 employees and becomes one of the largest employers in the combined state of Telangana/Andhra Pradesh
2017: Reaches the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad
2018: Market capital of $5B Reached
2018: 10 new production blocks commissioned
2018: Expanded the product portfolio to over 30 products
2019: Setting up Manufacturing plant at Kakinada
2019: Additional investment of $250M towards expansion of production blocks in Unit -I and Unit- II

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Divis Laboratories Ltd (DIVISLAB) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Divis Lab Share Price